NuCana (NCNA) Stock Price, News & Analysis

Company Overview

NuCana plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company uses its ProTide technology to create nucleotide analog medicines designed to improve the delivery and activity of existing chemotherapy agents while addressing mechanisms that can limit treatment effectiveness.

NuCana’s development portfolio has included NUC-1031, also known as Acelarin, a ProTide form of gemcitabine evaluated in several solid tumors. The company has also advanced NUC-3373, a ProTide-based fluoropyrimidine designed to deliver the active component of 5-fluorouracil, and NUC-7738, an investigational cancer therapy based on a nucleoside analog. These programs have been studied in clinical trials involving patients with different types of advanced cancer.

Founded in the United Kingdom, NuCana is headquartered in Edinburgh, Scotland, and has conducted clinical development activities in the United Kingdom, Europe and the United States. The company was founded by Hugh Griffith, who has served as its chief executive officer and has been involved in guiding its oncology-focused research and development strategy. NuCana’s shares trade on the Nasdaq under the symbol NCNA.

Key Stats

• Today's Range: $0.90 to $0.95
• 50-Day Range: $0.93 to $1.76
• 52-Week Range: $0.90 to $4.55
• Volume: 20,091 shs
• Average Volume: 30,508 shs
• Market Capitalization: $3.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

NuCana Stock Analysis - MarketRank™

NuCana scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

NuCana has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

NuCana has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NuCana is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NuCana is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NuCana has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.07% of the float of NuCana has been sold short.

Short Interest Ratio / Days to Cover

NuCana has a short interest ratio ("days to cover") of 1.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NuCana has recently increased by 45.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NuCana does not currently pay a dividend.

Dividend Growth

NuCana does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for NuCana this week, compared to 0 articles on an average week.

MarketBeat Follows

3 people have added NuCana to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NuCana insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/08/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:NCNA
• CIK: 1709626
• Web: www.nucana.com
• Phone: 441313571111
• Fax: N/A
• Employees: 11
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($3.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.71 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.90%
• Return on Assets: -33.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.73
• Quick Ratio: 4.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.71 per share
• Price / Book: 0.12

Miscellaneous

• Outstanding Shares: 4,160,000
• Free Float: 2,863,000
• Market Cap: $3.90 million
• Optionable: Not Optionable
• Beta: 2.39